These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

28 related articles for article (PubMed ID: 36631971)

  • 1. Research progress on the PEGylation of therapeutic proteins and peptides (TPPs).
    Li C; Li T; Tian X; An W; Wang Z; Han B; Tao H; Wang J; Wang X
    Front Pharmacol; 2024; 15():1353626. PubMed ID: 38523641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of proline-rich antimicrobial peptides as potential lead structures for novel antimycotics against
    Brakel A; Grochow T; Fritsche S; Knappe D; Krizsan A; Fietz SA; Alber G; Hoffmann R; Müller U
    Front Microbiol; 2023; 14():1328890. PubMed ID: 38260890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Readily adaptable release kinetics of prodrugs using protease-dependent reversible PEGylation.
    Böttger R; Knappe D; Hoffmann R
    J Control Release; 2016 May; 230():88-94. PubMed ID: 27067364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PEGylated prodrugs of antidiabetic peptides amylin and GLP-1.
    Böttger R; Knappe D; Hoffmann R
    J Control Release; 2018 Dec; 292():58-66. PubMed ID: 29729352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PEGylated Oligothioetheramide Prodrugs Activated by Host Serum Proteases.
    Artim CM; Kunala M; O'Leary MK; Alabi CA
    Chembiochem; 2021 Sep; 22(17):2697-2702. PubMed ID: 34227209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Species-specific optimization of PEG~SN-38 prodrug pharmacokinetics and antitumor effects in a triple-negative BRCA1-deficient xenograft.
    Fontaine SD; Hann B; Reid R; Ashley GW; Santi DV
    Cancer Chemother Pharmacol; 2019 Oct; 84(4):729-738. PubMed ID: 31321449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymeric prodrug combination to exploit the therapeutic potential of antimicrobial peptides against cancer cells.
    Kelly GJ; Kia AF; Hassan F; O'Grady S; Morgan MP; Creaven BS; McClean S; Harmey JH; Devocelle M
    Org Biomol Chem; 2016 Oct; 14(39):9278-9286. PubMed ID: 27722734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Vitro Properties and Pharmacokinetics of Temporarily PEGylated Onc72 Prodrugs.
    Mohammed GK; Böttger R; Krizsan A; Volke D; Mötzing M; Li SD; Knappe D; Hoffmann R
    Adv Healthc Mater; 2023 Apr; 12(11):e2202368. PubMed ID: 36631971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.
    Zhanel GG; Pozdirca M; Golden AR; Lawrence CK; Zelenitsky S; Berry L; Schweizer F; Bay D; Adam H; Zhanel MA; Lagacé-Wiens P; Walkty A; Irfan N; Naber K; Lynch JP; Karlowsky JA
    Drugs; 2022 Apr; 82(5):533-557. PubMed ID: 35294769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Releasable PEGylation of proteins with customized linkers.
    Filpula D; Zhao H
    Adv Drug Deliv Rev; 2008 Jan; 60(1):29-49. PubMed ID: 17884239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical studies of dendrimer prodrugs.
    Kojima C
    Expert Opin Drug Metab Toxicol; 2015; 11(8):1303-15. PubMed ID: 26028253
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.